Tracking the VNDA option chain helps you see every strike and expiry on Vanda Pharmaceuticals Inc in one view, so you can quickly identify the contracts that fit your thesis and your risk. Vanda Pharmaceuticals Inc's option chain lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of VNDA options activity at a glance. Use our scanner to monitor the VNDA option chain in real time and filter for the VNDA options trades that actually meet your criteria.
An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For VNDA stock options, the chain shows side-by-side call and put data, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading the VNDA option chain effectively means looking beyond the last price — implied volatility by strike, volume-to-open-interest ratios, and bid-ask spreads all tell you where VNDA stock options are being actively traded and where they are not.
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness.
The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Credit spreads, long calls, iron condors, calendar trades — every strategy starts with the same raw material: a clean, complete option chain. Our scanner pulls Vanda Pharmaceuticals Inc's full chain across every expiry, highlights the most liquid strikes, and lets you screen VNDA options by the metrics that matter, from IV skew to volume surges. Stop scrolling through endless rows of VNDA stock options — let the full option chain come to you, pre-filtered and ready to trade.
